Evidence map›Paper›PMID 31694682›Full record

ArticleTrials2019

Recruitment effort and costs from a multi-center randomized controlled trial for treating depression in type 2 diabetes.

Barbara A Myers, Yegan Pillay, W Guyton Hornsby, Jay Shubrook, Chandan Saha, Kieren J Mather, Karen Fitzpatrick, Mary de Groot

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Trials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03371940 (Program ACTIVE II), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03371940 nacompletednot on this map

Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes

TypeinterventionalSponsorIndiana UniversityRan2012 to 2017Enrolled140ConditionsType2 Diabetes, DepressionArmsProgram ACTIVE Exercise, Program ACTIVE CBT, Program ACTIVE, Usual Care - No intervention
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Shaken not stirred: Big data meets randomized controlled trial.Medical journal, Armed Forces India · 2021
    Article
  6. Article
  7. Review
  8. 50 Years of Behavioral Science in Diabetes: A 2020 Vision of the Future.Diabetes spectrum : a publication of the American Diabetes Association · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Barbara A MyersIndiana University School of Medicine, Diabetes Translational Research Center, 410 W 10th St, Suite 3100, Indianapolis, IN, 46202, USA.
Yegan PillayPatton College of Education, Ohio University, McCracken Hall 432M, Athens, OH, 45701, USA.
W Guyton HornsbyWest Virginia University School of Medicine, PO Box 9227, 8316 HSS, Morgantown, WV, 26506, USA.
Jay ShubrookCollege of Osteopathic Medicine, Touro University California, 1310 Club Dr, Vallejo, CA, 94592, USA.
Chandan SahaIndiana University School of Medicine, Diabetes Translational Research Center, 410 W 10th St, Suite 3100, Indianapolis, IN, 46202, USA.
Kieren J MatherIndiana University School of Medicine, Diabetes Translational Research Center, 410 W 10th St, Suite 3100, Indianapolis, IN, 46202, USA.
Karen FitzpatrickWest Virginia University School of Medicine, PO Box 9227, 8316 HSS, Morgantown, WV, 26506, USA.
Mary de GrootIndiana University School of Medicine, Diabetes Translational Research Center, 410 W 10th St, Suite 3100, Indianapolis, IN, 46202, USA. mdegroot@iu.edu.

Funding

Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
Program ACTIVE II: Behavioral Depression Treatment for Type 2 DiabetesR18DK092765 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DE GROOT, MARY K. · 2011 to 2015
$3.2M
NIDDK NIH HHS P30 DK097512NIDDK NIH HHS R18 DK092765NIDDK NIH HHS R18DK092765
6 · The paper itself

Abstract

backgroundParticipant recruitment for clinical trials is a significant challenge for the scientific research community. Federal funding agencies have made continuation of funding of clinical trials contingent on meeting recruitment targets. It is incumbent on investigators to carefully set study recruitment timelines and resource needs to meet those goals as required under current funding mechanisms. This paper highlights the cost, labor, and barriers to recruitment for Program ACTVE II, a successful multisite randomized controlled trial of behavioral treatments for depression in adults with type 2 diabetes, conducted in rural and urban settings in three states.

methodsQuantitative and qualitative data on recruitment were gathered from study staff throughout the study recruitment period and were used to calculate costs and effort. The study utilized two main approaches to recruitment: (1) relying on potential participants to see ads in the community and call a toll-free number; and (2) direct phone calls to potential participants by study staff.

resultsContact was attempted with 18,925 people to obtain the enrolled sample of 140. The cost of recruitment activities during the 4.5-year recruitment period totaled $190,056, an average cost of $1358 per enrolled participant. Qualitative evaluations identified multiple barriers to recruitment.

conclusionsRecruitment for Program ACTIVE II exemplifies the magnitude of resources needed to reach recruitment targets in the current era. Continuous evaluation, flexibility, and adaptation are required on the part of investigators, community partners, and funding agencies to successfully reach high-risk populations in rural and urban areas.

trial registrationClinicalTrials.gov, NCT03371940 . Registered on 13 December 2017.

Indexed as

Patient SelectionRandomized Controlled Trials as TopicCognitive Behavioral TherapyCosts and Cost AnalysisDepressionDiabetes Mellitus, Type 2Evaluation Studies as TopicExercise TherapyHumansClinical trialDepressionDiabetesStudy recruitment

Identifiers

PMID31694682
PMCPMC6836437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.